TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03834857

Intervention type: DEVICE
Group type: OTHER
Intervention: Stentrode
Description: Implantation of Stentrode device
Study: NCT04536142

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: A research MRI scan will be performed within 1 week prior to surgery and again 2 weeks after surgery. The surgical removal of the brain tumor(s) is not a component of this research. The MRI scan will perform both programs (diffusion MRI, resting state MRI) during the same single session. The healthy controls will obtain identical research scans with the second session between two and three weeks following the first session, since they will not undergo a surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests and qualitative assessment
Description: Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological tests and qualitative assessment
Description: Neuropsych Tests: COWA, Trails, RCFT, RAVLT, WMS-III subtests, NAB Digits, Grooved Pegboard, Stroop Color Word Test, verbal and spatial working memory, WRAT-IV, Word Reading subtest.~Standardized quality of life measures: MDASI-BT, FACT-Br, FrSBe
Study: NCT01977573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo

Intervention type: DRUG
Group type: OTHER
Intervention: rhEPO
Description: Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
Study: NCT02030067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-3117
Study: NCT02651662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administration via intravenous (IV) infusion. The dose(s) received will be according to dose level (DL) cohort assignment, as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odronextamab
Description: Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odronextamab
Description: Administration IV infusion. The dose(s) received will be according to DL cohort assignment, as described in the protocol.
Study: NCT03375866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pretzels
Description: Subjects consume 240 kcal of pretzels daily for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed nuts
Description: Subjects consume 240 kcal of mixed nuts daily for 16 weeks.
Study: NCT01045902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulbactam/Ampicillin
Description: Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
Study: NCT04477603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella ECP
Description: Subjects will receive the Impella ECP prior to high-risk percutaneous intervention. Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be followed until 30-days post-intervention.
Study: NCT02658279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT02101216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prurisol
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prurisol
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prurisol
Description: Experimental Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prurisol
Description: Experimental Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziagen
Description: Active comparator
Study: NCT02118467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
Study: NCT02619942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 radical operation
Description: In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Description: In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
Study: NCT01645215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
Study: NCT01955642

Intervention type: DRUG
Intervention: Clopidogrel
Description: 75 mg milligrams per days of PLAVIX
Study: NCT02786368

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHFP group
Description: Intervention group: training; inputs cost-sharing for EHFP activities.
Study: NCT01467531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: 50mg q 24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rlipivirine
Description: 25mg q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rlipivirine
Description: 25mg q24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744
Description: 30mg q24h
Study: NCT02195531

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and feedback
Description: The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
Study: NCT01818115

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IOL placement
Study: NCT01790087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-188 Therapeutic Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX-188 Supratherapeutic dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00602043

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Undergo \[\^18F\] FES PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo standard clinical FDG PET/CT
Study: NCT01441596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
Study: NCT00602043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo \[\^18F\] FES PET
Study: NCT00602043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo standard clinical FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo standard clinical FDG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04672694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vagus nerve block
Description: Ropivacine 0.75% 2mL will be injected two times around the vagus nerve (just below the bifurcation of recurrent laryngeal nerve); one before starting the surgical resection of lung including complete mediasitnal lymph node dissection and one at the end of operation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No vagus nerve block
Description: No vagus nerve block will be conducted during the surgery.
Study: NCT04469309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Brandt-Daroff Exercises
Description: In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group II Half-Somersault Maneuver
Description: In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
Study: NCT02852499

Intervention type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Intervention: Urine sampling

Intervention type: OTHER
Intervention: Carry a GPS and BET

Intervention type: OTHER
Intervention: Carry pollution sensor

Intervention type: OTHER
Intervention: Sampling at the maternity

Intervention type: OTHER
Intervention: Self-questionnaires

Intervention type: OTHER
Intervention: Self-questionnaires

Intervention type: OTHER
Intervention: Sampling in partum period
Description: Meconium and a strand of hair.
Study: NCT05114811

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-provided perineal massage
Description: External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapist perineal massage: manual and instrumental (with EPI-NO)
Description: The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device.
Study: NCT03370588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Group B: Saline infusion during same time period.
Study: NCT00595764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided Physician Management (PM)
Description: Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
Description: CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
Study: NCT01588522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound 31543 Calcitriol
Description: topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
Study: NCT03159494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Training
Description: 8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Training
Description: 8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed
Study: NCT00589628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 5mg/kg/dose IV at 4 week intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 10mg/kg/dose IV at 4 week intervals
Study: NCT00936065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept + Acitretin
Description: Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
Study: NCT02024724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 4 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 4 mL of 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg of Triamcinolone
Study: NCT00936065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Acitretin at a dose of 10mg BID for 24 weeks
Study: NCT00939211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Solution for inhalation through nebulization, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Solution for inhalation through nebulization, single dose
Study: NCT02970487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular implant of the Precisight
Description: Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
Study: NCT03062709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe Easy Coalition written materials
Description: written materials about secondhand and thirdhand environmental smoke exposure in children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maine Tobacco Helpline
Description: referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cotinine testing
Description: the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
Study: NCT02885402

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI Sodium ( 23Na )

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Sodium ( 23Na )
Study: NCT02024724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg of Dexamethasone
Study: NCT01430520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
Study: NCT02312934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Description: Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal Patch
Description: Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
Study: NCT03503617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehabTouch
Description: Exercise using the motion sensing devices and a computer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tabletop exercise program
Description: Exercise following printed sheets of exercises
Study: NCT02074657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated and expanded natural killer cells (NKAEs)
Description: Activated and expanded natural killer cells (NKAEs) from haploidentical donor
Study: NCT03205605

Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: patch

Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: patch

Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: gel

Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: gel
Study: NCT02815007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide with EGFR-TKI
Description: Chidamide and EGFR-TKI, dosage described in arm description.
Study: NCT01815996

Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA

Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA

Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA

Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA
Study: NCT02439021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA
Study: NCT01815996

Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA
Study: NCT00825786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine (15 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine (15 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: One syringe will contain mepivacaine (15 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: One syringe will contain mepivacaine (15 ml)
Study: NCT01231646

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a cross-sectional study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a cross-sectional study.
Study: NCT01101113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: cinacalcet 25mg qd or 50 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: vit D + P binder
Study: NCT03716362

Intervention type: DEVICE
Intervention: Otoacoustic emissions device
Description: as a screening tool for Auditory brainstem response
Study: NCT01005147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: 1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive placebo treatment as per the tranexamic acid schedule
Study: NCT01183169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study: NCT00258960

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Study: NCT02367976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhprouk
Description: rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed